NICHD SERVICES: Multipurpose Prevention Technologies (MPT) DATABASE ACCESS AND MAINTENANCE for Contraceptive Research

NICHD避孕研究处(CRB)正在进行与开发具有抗艾滋病毒、细菌性阴道病、衣原体等病原体感染性能的避孕技术有关的研究--多用途预防技术。 这份合同旨在支持促进多用途预防技术(MPT)开发中相关利益相关者之间的协调，包括产品开发商、资助机构、监管机构、学术研究人员、媒体和公众，以产品中立的能力帮助开发新型MPT。 注：MPTS是包含多种预防功能的产品，最常见的是由避孕药和艾滋病毒防护剂组成，但只要该产品至少有两个适应症，也可以含有其他抗感染药物。 ·知识维护 -汇编和托管与MPTS相关的资源，包括但不限于： A.目前正在开发的所有MPTS的最新数据库。 B.国家卫生研究院和其他国家和国际资助者与MPT开发商相关的当前资金机会公告。 C.该领域的最新新闻和出版物。 D.相关的网络研讨会、讲座等。 为对MPT研究感兴趣的受训者提供的资源。 F.为产品开发人员提供的资源，说明如何最好地将未被充分代表的选民纳入MPT研究。 G.对MPT开发中的利益相关者有用的任何其他相关资源。 ·协作和信息共享 -维护和扩大MPT开发的利益攸关方联系人名单，包括来自政府、学术界、行业、慈善机构和资助机构的人员。 -向这些利益攸关方提供与MPT领域相关的新闻、信息、出版物等的每月更新。 -组织和主办季度活动(研讨会、小组讨论、讲座等)关于与利益相关者相关的主题。四个主题中的一个必须与与MPT利益攸关方相关的多样性、公平性、包容性和可获得性(DEIA)特别相关。主题可以包括但不限于： A.解决MPT发展中的阴道健康问题。 B.将终端用户的意见纳入MPT产品开发。 C.将产品从临床前开发过渡到临床开发。 D.对MPT产品的监管考虑。 -通过以下方式充当当前和未来利益攸关方的沟通枢纽： A.促进当前MPT利益相关者之间的介绍和互动，特别是跨学科。 B.参与与潜在利益相关者的接触(前往相关会议并在相关会议上展示海报或演讲，与潜在资助者就MPTS进行接触) ·正在对MPT开发领域进行评估。 -至少出版一份出版物，评估MPT发展中的各种差距和障碍，包括克服这些问题的战略。主题可以包括但不限于： A.与MPT开发相关的Deia问题。 B.鼓励生物技术公司对MPT研发进行投资 C.将终端用户的意见纳入产品MPT产品开发流程。 D.概述并克服监管障碍，将MPTS推向市场。 E.对MPTS的未满足需求以及如何满足这些需求。 F.MPTS的新交付模式。

The NICHD Contraception Research Branch (CRB) is conducting research related to developing contraceptives technologies with anti-infective properties against pathogens such as HIV, Bacterial Vaginosis, Chlamydia, etc. – Multipurpose Prevention Technologies. This contract is to support facilitating coordination between relevant stakeholders in multipurpose prevention technology (MPT) development, including product developers, funding agencies, regulatory bodies, academic researchers, the media, and the public in a product neutral capacity to aid in the development of novel MPTs. Note: MPTs are products containing multiple preventative functions, most commonly they consist of a contraceptive plus an HIV preventative but can contain other anti-infectives as long as the product has at least two indications. • Knowledge maintenance - Compile and host resources relevant to MPTs including but not limited to: a. An up-to-date database of all MPTs currently under development. b. Current funding opportunities announcements relevant to MPT developers from NIH and other national and international funders. c. Recent news and publications in the field. d. Relevant webinars, lectures, etc. e. Resources for trainees interested in a career in MPT research. f. Resources for product developers on how best to include underrepresented constituencies in MPT research. g. Any other relevant resources that would be of use to stakeholders in MPT development. • Collaboration and information sharing - Maintain and grow a contact list of stakeholders in MPT development including people from government, academia, industry, philanthropy, and funding agencies. - Provide monthly updates to these stakeholders of relevant news, information, publications, etc. relevant to the MPT field. - Organize and host quarterly events (seminar, panel discussion, lecture, etc.) on a topic relevant to stakeholders. One of the four topics must be specifically related to Diversity, Equity, Inclusion, and Accessibility (DEIA) relevant to MPT stakeholders. Topics could include but would not be limited to: a. Addressing vaginal health in MPT development. b. Incorporating end-user input into MPT product development. c. Transitioning a product from pre-clinical to clinical development. d. Regulatory considerations for MPT products. - Act as a communication hub for current and future stakeholders by: a. Facilitating introductions and interactions between current MPT stakeholders, particularly across disciplines. b. Participating in outreach to potential stakeholders (traveling to and presenting posters or talks at relevant meetings, engaging with potential funders about MPTs) • Ongoing assessment of the MPT development field. - At least 1 publication assessing various gaps and barriers in MPT development, including strategies to overcome these issues. Topics could include but would not be limited to: a. DEIA issues relevant to MPT development. b. Encouraging investment from biotech companies into MPT R&D. c. Incorporating end-user input into the product MPT product development pipeline. d. Outlining and overcoming regulatory hurdles to get MPTs to market. e. The unmet need for MPTs and how to meet these needs. f. Novel delivery modalities for MPTs.